Lifecare ASA: Exercise price for Warrants Series 1 issued in connection with the Rights Issue

27 Feb 2026 19:06 CET

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED
STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE
PEOPLE'S REPUBLIC OF CHINA, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE
DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE.

Reference is made to the stock exchange announcement by Lifecare ASA (the
"Company") on 22 January 2026 regarding the final results of the partially
underwritten rights issue of new shares in the Company (the "Rights Issue").
Reference is also made to the announcement made by the Company on 30 January
2026 with information regarding the warrants issued in connection with the
Rights Issue.

A total of 129,000,033 warrants series 1 with ISIN NO0013709196 ("Warrants
Series 1") were allocated and delivered to the subscribers in and the
underwriters of the Rights Issue, pursuant to resolutions by the Company's
extraordinary general meeting held on 2 January 2026.

Each Warrant Series 1 gives the holder a right to subscribe for one new share
in the Company, each with a nominal value of NOK 0.10.

Warrants Series 1 may be exercised during the exercise period from 09:00 hours
(CET) on 2 March 2026 to 16:30 hours (CET) on 13 March 2026 (the "Exercise
Period"), at a subscription price per new share equal to 70% of the
volume-weighted average price (VWAP) of the Company's shares on Euronext Oslo
Børs on the last ten (10) trading days prior to the first date of the Exercise
Period, but in any event not exceeding NOK 0.625 (the subscription price in
the Rights Issue plus 25%). The subscription price may not be lower than the
par value of the Company's shares.

Based on the criteria above, the exercise price for Warrants Series 1 is NOK
0.3342 per new share.

Warrant Series 1 are listed and tradable on Euronext Oslo Børs under the
ticker codes "LIFEJ". The trading in Warrants Series 1 will be halted five
days before the end of the Exercise Period to facilitate settlement of
exercised Warrants Series 1. Warrants Series 1 will thus be tradable until
16:30 hours (CET) on 6 March 2026.

Warrants Series 1 not sold within 6 March 2026 at 16:30 (CET) or exercised
within 13 March 2026 at 16:30 (CET) will lapse with no compensation to the
holders. Holders of Warrants Series 1 who do not exercise their Warrants
Series 1 within the Exercise Period may experience a dilution of their
shareholding in the Company.

The exercise of Warrants Series 1 must be done through the submission of an
exercise form to the Managers (as defined below) or through the VPS online
subscription system, within the Exercise Period. Further information regarding
the exercise procedure, including weblinks to the exercise form, will be
provided in a separate stock exchange announcement to be published by the
Company before commencement of the Exercise Period.

DNB Carnegie, a part of DNB Bank ASA, and SB1 Markets AS act as managers in
the Rights Issue and the warrants exercise (the "Managers").

Important information

This announcement does not constitute an offer of securities for sale or a
solicitation of an offer to purchase securities of the Company in the United
States or any other jurisdiction. Copies of this announcement may not be sent
to jurisdictions, or distributed in or sent from jurisdictions, in which this
is barred or prohibited by law. The securities of the Company may not be
offered or sold in the United States absent registration or an exemption from
registration under the U.S. Securities Act of 1933, as amended (the "U.S.
Securities Act"). The securities of the Company have not been, and will not
be, registered under the U.S. Securities Act. Any sale in the United States of
the securities mentioned in this communication will be made solely to
"qualified institutional buyers" as defined in Rule 144A under the U.S.
Securities Act. No public offering of the securities will be made in the
United States.

This announcement is an advertisement and is not a prospectus for the purposes
of Regulation (EU) 2017/1129 of the European Parliament and of the Council of
14 June 2017 on prospectuses to be published when securities are offered to
the public or admitted to trading on a regulated market, and repealing
Directive 2003/71/EC (as amended) as implemented in any EEA Member State (the
"Prospectus Regulation").

This announcement is not for publication or distribution in, directly or
indirectly, Australia, Canada, Japan, the United States, or any other
jurisdiction in which such release, publication or distribution would be
unlawful, and it does not constitute an offer or invitation to subscribe for
or purchase any securities in such countries or in any other jurisdiction. In
particular, the document and the information contained herein should not be
distributed or otherwise transmitted into the United States or to publications
with a general circulation in the United States of America.

The Managers are acting for the Company in connection with the Rights Issue
and no one else and will not be responsible to anyone other than the Company
for providing the protections afforded to their respective clients or for
providing advice in relation to the Rights Issue or any transaction or
arrangement referred to in this announcement.

Matters discussed in this announcement may constitute forward-looking
statements. Forward-looking statements are statements that are not historical
facts and may be identified by words such as "anticipate", "believe",
"continue", "estimate", "expect", "intends", "may", "should", "will" and
similar expressions. The forward-looking statements in this release are based
upon various assumptions, many of which are based, in turn, upon further
assumptions. Although the Company believes that these assumptions were
reasonable when made, these assumptions are inherently subject to significant
known and unknown risks, uncertainties, contingencies, and other important
factors which are difficult or impossible to predict and are beyond its
control. Such risks, uncertainties, contingencies, and other important factors
could cause actual events to differ materially from the expectations expressed
or implied in this release by such forward-looking statements. The
information, opinions and forward-looking statements contained in this
announcement speak only as at its date and are subject to change without
notice. This announcement is made by and is the responsibility of the Company.

Neither the Managers nor any of their respective affiliates make any
representation as to the accuracy or completeness of this announcement and
none of them accepts any responsibility for the contents of this announcement
or any matters referred to herein.

This announcement is for information purposes only and is not to be relied
upon in substitution for the exercise of independent judgment. It is not
intended as investment advice and under no circumstances is it to be used or
considered as an offer to sell, or a solicitation of an offer to buy any
securities or a recommendation to buy or sell any securities of the Company.
No reliance may be placed for any purpose on the information contained in this
announcement or its accuracy, fairness, or completeness. Neither the Managers
nor any of their respective affiliates accept any liability arising from the
use of this announcement.

About us
Lifecare ASA is a medical sensor company developing technology for sensing and
monitoring of various body analytes. Lifecare's focus is to bring the next
generation of Continuous Glucose Monitoring systems to market. Lifecare
enables osmotic pressure as sensing principle. Lifecare's sensor technology is
suitable for identifying and monitoring the occurrence of a wide range of
analytes and molecules in the human body and in pets.

Contacts
For further information, please contact:

Joacim Holter, CEO, joacim.holter@lifecare.no, +47 40 05 90 40

Renete Kaarvik, CFO, renete.kaarvik@lifecare.no, +47 94 83 82 42

This information is subject to disclosure under the Norwegian Securities
Trading Act, §5-12. The information was submitted for publication, through the
agency of the contact persons set out above, at 2026-02-27 19:06 CET.

More information:
Access the news on Oslo Bors NewsWeb site

667180_Lifecare ASA- Exercise price for Warrants Series 1 issued in connection with the Rights Issue.pdf